NeuroScientific's StemSmart Therapy Manufacturing Milestone

0:00It's March 17th. Here's your Sydney news in two minutes. Neuroscientific Bio Pharmaceuticals has launched its first manufacturing run for the StemSmart Stem Cell Therapy at a top facility in Brisbane, Australia. The company is transferring its patented production process to QGIN's cell therapeutics, located at the QIMR Burkhofer Medical Research Institute. This step boosts manufacturing capacity for upcoming clinical trials, targeting Crohn's disease. QGIN operates one of Australia's largest cell therapy sites, with 13 clean rooms for production and quality control. The transfer is now in the engineering and demonstration phase, where batches must meet strict standards for quality and potency. Full completion is expected in the second half of 2026, pending regulatory approval from Australia's therapeutic goods administration. Early results from a special access program have been promising, with three out of four patients with Fiscializing Crohn's disease showing strong responses, and the fourth improving.

1:01The chief executive called this partnership key to securing a reliable supply chain for high quality treatments. Patients with severe cases often face limited options as many drugs lose effectiveness over time. StemSmart uses mesenchymal stem cells to reduce inflammation and support tissue repair, offering a fresh approach beyond symptom relief. The global Crohn's market could reach $13.8 billion USD by the end of 2026. Neuroscientific is preparing a phase 2 trial set to start in the second half of this year. Looking ahead, success here could pave the way for commercial supply and expand StemSmart to other immune-related conditions, like transplant rejection, or lung diseases. This manufacturing milestone positions the company for late-stage trials and potential patient access down the line. Hope for this episode comes from our sponsor, see the description. Some chase peace, I put my head in it. S-O-L-I-SoliPillow.com